Lumida
/RZLT
⌘K
Rezolute Inc

Rezolute Inc

RZLT
$4.61USD↑+5.49%+0.24 today

MARKET CAP

443.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $5

52W RANGE

$1
$11

AI Summary

Stalk
StalkMedium

RZLT remains in a Stage 2 advancing regime with a recent momentum breakout confirming demand. The medium-term bias is bullish and aligns with the established uptrend, but short-term conditions are unfavorable as price is extended above rising EMAs and in extreme overbought territory. Execution is deferred toward pullbacks into the breakout zone and rising EMAs for selective entry.

  • ↑Phase 3 sunRIZE trial expanded analyses show efficacy in hyperinsulinism.
  • ↑Institutional 13F ownership high, signaling robust institutional support.
  • ↓Negative profitability metrics highlight difficulty sustaining earnings generation.
Full analysis →
Insider Trades33 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Jul 2, 2026SellRZLTDaron EvansCFO3,062$4.99$443.9M-59.76%+330.84%$15.3K-0.74%—Stalk
Jul 2, 2026SellRZLTBrian Kenneth RobertsChief Medical Officer3,062$4.99$443.9M-59.76%+330.84%$15.3K-1.03%—Stalk
Jul 2, 2026SellRZLTNevan C ElamCEO8,004$4.99$443.9M-59.76%+330.84%$39.9K-1.30%—Stalk
Mar 30, 2026BuyRZLTDaron EvansCFO10,000$2.85$443.9M-59.76%+330.84%$28.5K+2.47%—Stalk
Mar 2, 2026SellRZLTDaron EvansCFO11,438$2.99$443.9M-59.76%+330.84%$34.2K-2.75%—Stalk
Mar 2, 2026SellRZLTBrian Kenneth RobertsChief Medical Officer11,439$2.99$443.9M-59.76%+330.84%$34.2K-3.71%—Stalk
Mar 2, 2026SellRZLTNevan C ElamCEO27,618$2.99$443.9M-59.76%+330.84%$82.6K-4.31%—Stalk
Dec 16, 2025BuyRZLTBrian Kenneth RobertsChief Medical Officer28,000$1.70$443.9M-59.76%+330.84%$47.6K+9.99%—Stalk
Dec 15, 2025BuyRZLTSunil Ratilal KarnawatChief Commercial Officer12,100$1.62$443.9M-59.76%+330.84%$19.6K+9.24%—Stalk
Dec 15, 2025BuyRZLTNevan C ElamCEO32,000$1.59$443.9M-59.76%+330.84%$50.9K+5.25%—Stalk
Dec 15, 2025BuyRZLTDaron EvansCFO45,000$1.77$443.9M-59.76%+330.84%$79.6K+11.69%—Stalk
Dec 9, 2025BuyRZLTDaron EvansCFO10,549$5.04$443.9M-59.76%+330.84%$53.2K+8.69%—Stalk
Jun 25, 2025BuyRZLTBrian Kenneth RobertsChief Medical Officer2,500$4.38$443.9M-59.76%+330.84%$10.9K+19.23%—Stalk
Jun 24, 2025BuyRZLTDaron EvansCFO5,000$4.05$443.9M-59.76%+330.84%$20.3K+1.89%—Stalk
Mar 27, 2025BuyRZLTNevan C ElamCEO12,302$2.85$443.9M-59.76%+330.84%$35.0K+5.81%—Stalk
Mar 26, 2025BuyRZLTDaron EvansCFO20,000$2.88$443.9M-59.76%+330.84%$57.7K+8.30%—Stalk
Dec 18, 2024BuyRZLTDaron EvansCFO10,000$4.29$443.9M-59.76%+330.84%$42.9K+7.10%—Stalk
Dec 12, 2024BuyRZLTDaron EvansCFO9,000$4.60$443.9M-59.76%+330.84%$41.4K+6.82%—Stalk
Jun 14, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer7,600$3.91$443.9M-59.76%+330.84%$29.7K+6.60%—Stalk
Jun 14, 2024BuyRZLTDaron EvansCFO40,000$4.04$443.9M-59.76%+330.84%$161.6K——Stalk
May 29, 2024BuyRZLTDaron EvansCFO451$3.50$443.9M-59.76%+330.84%$1.6K+0.37%—Stalk
May 23, 2024BuyRZLTDaron EvansCFO3,000$3.22$443.9M-59.76%+330.84%$9.7K+14.96%—Stalk
May 23, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer7,500$2.69$443.9M-59.76%+330.84%$20.1K+8.66%—Stalk
Mar 28, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer500$2.55$443.9M-59.76%+330.84%$1.3K+86.81%—Stalk
Mar 15, 2024BuyRZLTDaron EvansCFO20,000$1.69$443.9M-59.76%+330.84%$33.8K——Stalk
Mar 14, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer10,000$1.88$443.9M-59.76%+330.84%$18.8K——Stalk
Mar 8, 2024BuyRZLTDaron EvansCFO50,000$1.93$443.9M-59.76%+330.84%$96.3K+70.52%—Stalk
Mar 7, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer500$1.85$443.9M-59.76%+330.84%$925——Stalk
Mar 7, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer500$1.85$443.9M-59.76%+330.84%$925+657.89%—Stalk
Feb 26, 2024BuyRZLTNevan C ElamCEO5,000$1.68$443.9M-59.76%+330.84%$8.4K+177.49%—Stalk
Feb 23, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer8,000$1.69$443.9M-59.76%+330.84%$13.5K+10.65%—Stalk
Feb 16, 2024BuyRZLTBrian Kenneth RobertsChief Medical Officer7,000$1.31$443.9M-59.76%+330.84%$9.1K+25.41%—Stalk
Feb 16, 2024BuyRZLTDaron EvansCFO50,900$1.31$443.9M-59.76%+330.84%$66.7K+175.52%—Stalk